Because HIV-infected patients are more susceptible to herpes zoster infection than the average person, researchers wanted to test the value of a vaccine to determine if it provides protection for this vulnerable population. Their randomized controlled trial (RCT) concluded that it does.
- The RCT, which was double-blind and placebo controlled, involved 395 HIV-infected adults, all of whom were on antiretroviral medication and were virologically suppressed.
- Injection site reactions occurred in 42% of patients on the live attenuated vaccine, compared to 12.4% of those on placebo.
- Herpes zoster vaccine antibody titers were significantly higher in patients who received the vaccine.
- Vaccine antibody titers were similar for patients on 1 or 2 doses.
- Investigators concluded that 2 doses of the vaccine in patients with CD4+ counts at or above 200 cells/µL is safe and immunogenic.
Benson CA, Andersen JW, Macatangay BJC, et al. Safety and immunogenicity of zoster vaccine live in HIV-Infected adults with CD4+ Cell counts above 200 cells/mL virologically suppressed on antiretroviral therapy. [Published online ahead of print March 26, 2018]. Clin Infect Dis. doi:10.1093/cid/ciy242.
This Week's Must Reads
Must Reads in Vaccines
Vaccination for Prevention of Herpes Zoster, Ann Intern Med; ePub 2019 Feb 19; Prosser, et al